Monday, December 15, 2025

Latest

AMD: Analysts Call For Q2 Revenues Of $6.55 Billion

Advanced Micro Devices (NASDAQ: AMD) will be reporting its second quarter financial results today after market close. Analysts have a consensus $128.11 12-month price target on the company, via a total of 42 analysts, with nine analysts having strong buy ratings.

19 analysts meanwhile have buy ratings, 13 analysts have hold ratings and a single analyst has a sell rating on the stock. The street high comes from Elazar Advisors with a $230 price target, and the lowest target sits at $85.

26 analysts have revenue estimates for the second quarter. The mean revenue estimate between all 26 analysts is $6.55 billion; this number has been revised upwards since the start of the year. The highest revenue estimate is $6.7 billion, while the lowest is $6.5 billion.

Onto EBITDA estimates, there are currently only 4 analysts who have second-quarter EBITDA estimates. The mean is currently $2.1 billion. The estimate has been revised lower since the start of the year. Street high is a $2.1 billion EBITDA estimate, and the lowest is $2 billion.

Analysts estimate that quarterly earnings per share will come in at $1.03, up from the $0.78 estimate at the start of the year. The street high estimate is $1.16, and the lowest estimate is $0.97 per share for the quarter.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to the organizations discussed. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Soma Gold: Q3 Earnings Impacted By Labour Strike

Thesis Gold: The Multi-Billion Dollar Lawyers-Ranch PFS

Why Canada Has So Few Projects That Can Be Built Before 2030 | Dan Wilton – First Mining

Recommended

Steadright Locks Up Goundafa Polymetallic Mine Under Binding MOU

Emerita Resources Awards Contract For Pre-Feasibility Study On Iberian Belt West Project

Related News

Canaccord Raises Mind Medicine’s Price Target To $2.00 Following Financing

This morning, Canaccord Genuity raised its 12-month price target on Mind Medicine (NEO: MMED) from...

Monday, November 2, 2020, 10:45:02 AM

Hexo: Stifel-GMP Puts Bankruptcy On The Table For Company Following Terrible Debt Deal

On October 29th, Hexo Corp (TSX: HEXO) reported its fiscal fourth quarter financial results. The...

Monday, November 8, 2021, 03:58:00 PM

Bank Of America Upgrades Canopy Growth’s Price Target To C$36 From C$30

Last week, Canopy Growth (TSX: WEED) (NASDAQ: CGC) reported its fiscal second quarter 2021 financial...

Wednesday, November 18, 2020, 09:59:00 AM

ReconAfrica: Haywood Lifts Price Target To $16.00 Following Operational Update

On June 24th, ReconAfrica (CVE: RECO) provided an operational and COVID-19 update, wherein the company...

Monday, June 28, 2021, 11:36:00 AM

Canaccord Initiates Coverage On Uranium Royalty Corp With $1.60 Price Target

This morning Canaccord Genuity’s Katie Lachapelle initiated coverage on Uranium Royalty Corp (TSXV: URC) with...

Tuesday, September 8, 2020, 03:17:18 PM